

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

5,000

Open access books available

125,000

International authors and editors

140M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.  
For more information visit [www.intechopen.com](http://www.intechopen.com)



---

# Molecular and Cellular Mechanism of Muscle Regeneration

---

Kunihiro Sakuma and Akihiko Yamaguchi

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/48229>

---

## 1. Introduction

Skeletal muscle contractions power human body movements and are essential for maintaining stability. Skeletal muscle tissue accounts for almost half of the human body mass and, in addition to its power-generating role, is a crucial factor in maintaining homeostasis. Given its central role in human mobility and metabolic function, any deterioration in the contractile, material, and metabolic properties of skeletal muscle has an extremely important effect on human health.

Several possible mechanisms for age-related muscle atrophy have been described; however the precise contribution of each is unknown. Age-related muscle loss is a result of reductions in the size and number of muscle fibers [1] possibly due to a multi-factoral process that involves physical activity, nutritional intake, oxidative stress, and hormonal changes [2-4]. The specific contribution of each of these factors is unknown but there is emerging evidence that the disruption of several positive regulators [Akt and serum response factor (SRF)] of muscle hypertrophy with age is an important feature in the progression of sarcopenia [5-7]. In addition, sarcopenia seems to include the defect of muscle regeneration probably due to the repetitive muscular damage. Indeed, the group of Conboy [8-10] indicates that Notch-dependent signaling is impaired in sarcopenic muscle.

Upon tissue injury, the cues released by the inflammatory component of the regenerative environment instruct somatic stem cells to repair the damaged area [11]. The elucidation of the molecular events underpinning the interplay between the inflammatory infiltrate and tissue progenitors is crucial to devise new strategies toward implementing regeneration of diseased or injured tissues. Regeneration of diseased muscles relies on muscle stem cells (satellite cells) located under the basal lamina of muscle fibers [12], which are activated in response to cytokines and growth factors [13]. The current lack of knowledge of how

external cues coordinate gene expression in these cells precludes their selective manipulation through pharmacological interventions.

The inflammatory infiltrate is a transient, yet essential, component of the satellite cell niche and provides the source of locally released cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), which regulate muscle regeneration [14]. As an inducible element of the satellite cell niche, the inflammatory infiltrate provides an ideal target for selective interventions aimed at manipulating muscle regeneration [15]. However, because local inflammation regulates multiple events within the regeneration process, global anti-inflammatory interventions have both positive and negative effects on satellite cells [16]. Thus, it is important to elucidate the intracellular signaling by which inflammatory cytokines deliver information to individual genes in satellite cells.

Similarly to the embryonic stem cells that build organs, adult stem cells that regenerate organs are capable of symmetric and asymmetric division, self-renewal, and differentiation. This precise coordination of complex stem cell responses throughout adult life is regulated by evolutionally conserved signaling networks that cooperatively direct and control (1) the breakage of stem cell quiescence, (2) cell proliferation and self-renewal, (3) cell expansion and prevention of premature differentiation and finally, (4) the acquisition of terminal cell fate. This highly regulated process of tissue regeneration recapitulates embryogenic organogenesis with respect to the involvement of interactive signal transduction networks such as hepatocyte growth factor (HGF), Notch, MyoD, calcineurin, and SRF [17, 18]. This review aims to outline the molecular and cellular mechanisms of muscle regeneration.

## 2. Early immune response

Two distinct macrophage populations exist. Classically activated (or type I) macrophages are induced by interferon (IFN)- $\gamma$ , alone or in concert with microbial stimuli (e.g. lipopolysaccharide) or selected cytokines (e.g. TNF- $\alpha$  and granulocyte macrophage colony-stimulating factor). They have pro-inflammatory functions: classically activated macrophages produce effector molecules (reactive oxygen and nitrogen intermediates) and inflammatory cytokines (IL-1 $\beta$ , TNF- $\alpha$ , IL-6), participate as inducer and effector cells in polarized Th1 responses, and mediate resistance against intracellular parasites and tumors. Type I macrophages characteristically and selectively express pro-inflammatory chemokines, in particular CCL [chemokine (C-C motif) ligand] 3. Alternatively activated (or type II) macrophages comprise cells exposed to IL-4 or IL-13, immune complexes, IL-10, and glucocorticoid; they participate in polarized Th2 reactions, promote killing and encapsulation of parasites, and are present in established tumors, where they promote progression. Moreover, alternatively activated macrophages are involved in wound healing and have immunoregulatory functions [18]. The expression of membrane receptors, like the hemoglobin scavenger receptor CD163, unambiguously identifies type II macrophages [19].

Studies in the rat have shown that type I macrophages are associated with muscle necrosis, whereas type II macrophages are associated with regenerative myofibers [20]. Of striking

interest, these cells, once within the muscle, apparently acquire a type II phenotype, revealing a previously ignored plasticity. What are the signals that trigger the shift? Recognition and phagocytosis of muscle cell debris is probably a critical event. Indeed while type I macrophages enhance the proliferation of local myogenic precursor cells, type II macrophages stimulate their fusion and differentiation [21]. Some molecular interactions are required for macrophage recruitment and function in damaged muscles. The muscle tissue of mice with a null mutation of CCR2, the CCL2 receptor, undergoes regenerating defects including fibrosis and calcification after muscle damage. In addition, uPA (urokinase-type plasminogen activator)-/- macrophages fail to infiltrate damaged muscle [22]. This failure is associated with defective muscle regeneration, demonstrating that uPA is required for the homeostatic response to injury. Mice lacking an inhibitor of uPA, PAI-1 (plasminogen activator inhibitor 1), exhibit increased uPA activity: injured muscle of PAI-1-/- mice shows evidence of increased macrophage accumulation, and of accelerated muscle repair [23]. Expression of uPA is apparently required for the expression of insulin-like growth factor-I (IGF-I), a central regulator of muscle regeneration [24]. IGF-I suppresses the expression and activity of macrophage migration inhibitory factor and the transcription factor NF- $\kappa$ B, possibly directly regulating the persistence of inflammatory responses [25, 26].

### 3. Hepatocyte growth factor and neuronal nitric oxide synthase

By 24 hours after muscle injury, satellite cells enter the G1/S phase of the cell cycle [27]. Two factors have been demonstrated to activate quiescent satellite cells. The first is HGF. Early experiments using single muscle fibers with associated quiescent satellite cells have shown that growth factors, such as IGF-I and fibroblast growth factor (FGFs), do not activate satellite cells in fibers [28, 29]. Although IGF-I and FGFs are reported to activate satellite cells, the studies involved typically used cultures of muscle cells that were not quiescent; IGF-I and FGFs increase the proliferative activity of satellite cells once they are activated, even when that activation results during the cell isolation process, i.e. prior to the plating of cells or fibers for culture. Moreover, platelet-derived growth factor BB, transforming growth factor- $\beta$  (TGF- $\beta$ ), and epidermal growth factor do not stimulate quiescent cells to enter the cell cycle *in vitro* [30, 31]. Therefore, HGF is the only growth factor that has been established to have the ability to stimulate quiescent satellite cells to enter the cell cycle early in a culture assay and *in vivo* [32, 33]. HGF is localized to the extracellular domain of un-injured skeletal muscle fibers through a possible association with glycosaminoglycan chains of proteoglycans that are essential components of the extracellular matrix, and following injury, quickly associates with satellite cells [34] by binding to its receptor, c-Met [33].

The second component shown to be involved in satellite cell activation is nitric oxide (NO), possibly through activation of matrix metalloproteinases (MMP), which induce the release of HGF, from the extracellular matrix [34, 35]. Studies *in vitro* and *in vivo* using rodent muscle have shown HGF and NO to regulate the activity of many satellite cells [33, 34, 36, 37]. Intriguingly, inhibition of NO production inhibits HGF release, c-Met/HGF co-

localization, and satellite cell activation [34]. NO is a short-lived free radical that is well known as a freely diffusible and ubiquitous molecule produced by nitric oxide synthase (NOSs) from the L-arginine of substrates. In skeletal muscle, neuronal NOS (nNOS, also called NOS-1) is localized to the sarcolemma of muscle fibers by association at its amino terminus with alpha1-syntrophin linked to the dystrophin cytoskeleton [38]. The NO radical is normally produced in very low level pulses by muscles under conditions where satellite cells are quiescent [39], and the expression and activity of constitutive NOS (nNOS and eNOS) are up-regulated by exercise, loading injury, shear force, and mechanical stretch. NO also induces expression of follistatin [40], a fusigenic secreted molecule, known to antagonize myostatin, thus possibly contributing to the exit of satellite cells from quiescence.

More recently, Tatsumi and Allen [37] proposed the intriguing hypothesis that HGF has another role in satellite cells. Although, in culture, a low level of HGF (2.5 ng/ml) optimally stimulates the activation of satellite cells, high levels of HGF (10-500 ng/ml) promote the re-entering of quiescence through a concentration-dependent negative feedback mechanism. Such a role seems to be regulated by the induction of the cyclin-dependent kinase (CDK) inhibitor p21 in a myostatin-dependent manner. Further descriptive analysis is needed to elucidate whether HGF and myostatin really do interact in skeletal muscle *in vivo*. Tatsumi and Allen [37] suggested the importance and difficulty of monitoring whether or not extracellular HGF concentrations reach a threshold (over 10 ng/ml) in muscle of living animals.

## 4. The proliferating process of satellite cells

### 4.1. Leukemia inhibitory factor

Leukemia inhibitory factor (LIF) is a newly discovered myokine [41], originally identified by its ability to induce the terminal differentiation of myeloid leukemic cells. Today, LIF is known to have a wide array of functions, including acting as a stimulus for platelet formation, the proliferation of hematopoietic cells, bone formation, neural survival and formation, muscle satellite cell proliferation and acute phase production by hepatocytes [42]. LIF is a long chain four  $\alpha$ -helix bundle cytokine, which is highly glycosylated and may be present with a weight of 38-67 kDa, which can be deglycosylated to ~20 kDa [43, 44]. Several tissues, including skeletal muscle, express LIF. LIF is constitutively expressed at a low level in type I muscle fibers [45, 46] and is implicated in conditions affecting skeletal muscle growth and regeneration [45-47]. Indeed, LIF knockout mice showed a decrease in the area occupied by regenerating myofibers after crush injury compared to wild-type mice, which was restored by administration of exogenous LIF [48]. Administration of LIF to the site of crush injury in wild-type mice increased the area occupied by regenerating fibers with an associated increase in average myofiber diameter [48, 49]. These original studies suggested that enhanced regeneration and increases in fiber size occurred, at least in part via stimulation of the proliferation of muscle-forming myoblast cells, thus providing more cells to fuse to and increase the size of regenerating fibers.

In 1991, Austin and co-workers demonstrated that LIF stimulated myoblast proliferation in culture [50], thereby showing that LIF functions as a mitogenic growth factor when added to muscle precursor cells *in vitro*. To date, different groups have confirmed this finding and shown that LIF induces satellite cell and myoblast proliferation, while preventing premature differentiation, by activating a signaling cascade involving Janus kinase 1 (JAK1), signal transducer and activator of transcription (STAT) 1, and STAT3 [51, 52]. In line with this, the specific LIF receptor is primarily expressed by satellite cells and not by mature muscle fibers [53]. Thus, it seems that LIF has the potential to affect satellite cells rather than mature muscle fibers.

Earliest descriptions of LIF as a possible mitogen for myoblasts suggested that LIF treatment increased the number of human and mouse-derived primary myoblast cells in a dose-dependent manner after several days of culture, with the earliest increases noticeable after 6 days [50, 54]. There is evidence to suggest that LIF promotes survival of myoblasts and other cell types [55, 56]. Hunt et al. [57] found that LIF treatment significantly reduced staurosporine-induced apoptotic DNA fragmentation by 37% and also reduced the proteolytic activation of caspase-3 by 40% compared to controls. This apoptosis-inhibiting role of LIF was completely abolished by a PI3-K (phosphatidylinositol 3-kinase) inhibitor (wortmannin). Therefore, LIF appears to increase the number of satellite cells by promoting proliferation and blocking apoptosis.

#### **4.2. Insulin-like growth factor-I and MAPK (proliferation phase)**

The anabolic effects of IGF-I have been demonstrated in both muscle cell lines and animal models [58-60]. For example, the addition of IGF-I to cultured myotubes results in an enlargement of myotube diameters and a higher protein content, while the delivery of IGF-I either through osmotic pumps or genetic overexpression results in increased muscular mass in rodents [24, 58]. Mechanical loading also results in skeletal muscle synthesis of IGF-I [61, 62] *in vivo*, which stimulates gene expression, DNA and protein synthesis, different transport mechanisms, migration, proliferation, and differentiation [63]. Therefore, investigators conclude that IGF-I is a critical factor involved in skeletal muscle hypertrophy *in vivo* as well as in cultured myotube enlargement *in vitro*.

IGF-I is thought to induce muscle growth through the increased proliferation of satellite cells and the enhancement of protein translation resulting in an increase in the rate of protein synthesis [63, 64]. In addition to stimulating myoblast proliferation, IGF-I stimulates myoblast differentiation [65]. For example, IGF-I inhibits production of myogenin, a protein that stimulates muscle cell differentiation, thus allowing increased myoblast proliferation. It is known that the binding of IGF-I to its receptor, after tyrosine (auto)phosphorylation of the receptor, results in the initiation of intracellular cascades of various kinase systems. However, the interplay between the elements of these intracellular signaling pathways has been described based on results of experiments with skeletal muscle cell types of different species and under various conditions. Namely, in mouse and rat skeletal muscle preparations, the involvement of both the MAPK (mitogen-activated protein kinase)

pathway and MAPK-independent signaling mechanisms, including PI3-K/Akt and protein kinase C (PKC), was equally documented [66-68]. In primary cultured human skeletal muscle cells, Czifra et al. [69] demonstrated that the proliferation-enhancing effect of IGF-I was completely inhibited by the PKC $\delta$ -specific inhibitor Rottlerin but not by inhibitors of the “conventional” PKC $\alpha$  and  $\gamma$  isoforms or by inhibitors of the MAPK or PI3-K pathway. In addition, overexpression of a kinase inactive mutant of PKC $\delta$  prevented the proliferating action of IGF-I. Furthermore, they showed, in mouse C2C12 cells, that the MAPK inhibitor PD098059 partially inhibited the action of IGF-I. Taken together, these results demonstrate a novel, central and exclusive involvement of PKC $\delta$  in mediating the action of IGF-I in human skeletal muscle cells, with an additional yet PKC $\delta$ -dependent contribution of the MAPK pathway in C2C12 myoblasts.

### 4.3. Notch-dependent signaling

The proliferating process in satellite cells appears to be controlled by Notch signaling during muscle regeneration [70]. Within hours to days following muscle injury, there is increased expression of Notch signaling components (Delta-1, Notch-1 and active Notch) in activated satellite cells and neighboring muscle fibers [8, 70]. Up-regulation of Notch signaling promotes the transition from activated satellite cells to highly proliferative myogenic precursor cells and myoblasts, as well as prevents differentiation to form myotubes [8, 71, 72]. Proliferation was decreased and differentiation was promoted when Notch activity was inhibited in myoblasts with a Notch antagonist, Numb, a gamma-secretase inhibitor, or with small-interfering RNA (siRNA) knockdown of presenilin-1 [70, 71, 73]. In addition, mutations in Delta-like 1 or CSL result in excessive premature muscle differentiation and defective muscle growth [74]. Apparent impairment of Notch signaling occurs in aged muscle, because expression of the Notch ligand, Delta, is not upregulated following injury in this muscle. Forced activation of this pathway with a Notch-activating antibody can restore the regenerative potential by inducing the expression of several positive regulators (PCNA, Cyclin D1) of cell cycle progression [8, 9].

A recent study revealed that levels of TGF- $\beta$  are higher in aged than young satellite cell niches [10]. Further analysis showed greater activation of the TGF- $\beta$  pathway in old satellite cells, and physical competition between Notch and pSmad3 at the promoters of multiple CDK inhibitors [10, 75]. Furthermore, the decline of Notch1 signaling with age is thought to be another cause of the decreased regenerative potential of aged skeletal muscle. Indeed, enhancement of Notch-1 signaling promotes muscle regeneration in old skeletal muscle [8, 9]. Although these experiments suggest a crucial role for Notch1 signaling in satellite cell function, much remains to be determined, especially regarding the role of Notch3 signaling during muscle regeneration. Notch3 was expressed in satellite cells, and various structural and functional differences between Notch3 and Notch1/Notch2 have been reported [76]. More recently, Kitamoto and Hanaoka [77] conducted two very intriguing experiments. They analyzed muscle after repeated injuries, by generating mice deficit in Notch3 and also by repetitive intramuscular injections of cardiotoxin (CTX) into the Notch3-deficient mice.

They found a remarkable overgrowth of muscle mass in the Notch3-deficient mice but only when they suffered repetitive muscle injuries. Analysis of cultured myofibers revealed that the number of self-renewing Pax7-positive satellite cells attached to myofibers was increased in the Notch3-deficient mice compared to control mice. Given these findings, the Notch3 pathway might act as a Notch1 repressor by activating Nrarp, a negative feedback regulator of Notch signaling.

## 5. The differentiation of satellite cells

### 5.1. MyoD family

Satellite cell myogenic potential mostly relies on the expression of Pax genes and myogenic regulatory factors (MRFs: MyoD, Myf5, myogenin, and MRF4). Sequential activation and expression of Pax3/7 and MRFs is required for the progression of skeletal myoblasts through myogenesis. Pax7 is expressed by all satellite cells and essential to their postnatal maintenance and self-renewal [78]. Pax7 induces myoblast proliferation and delays their differentiation not by blocking myogenin expression [79] but by regulating MyoD [80]. In parallel, myogenin directly down-regulates Pax7 protein expression during differentiation [80]. MyoD is required for the differentiation of skeletal myoblasts [81, 82]. In addition, MyoD null satellite cells showed reduced myogenin expression and absolutely no MRF4 expression, and displayed a dramatic differentiation deficit [82]. Indeed, muscle regeneration *in vivo* is markedly impaired in MyoD null mice [83]. In contrast, Myf5 regulates the proliferation rate and homeostasis [84]. MyoD can compensate for Myf5 in adults. Myf5 deficiency leading to a lack of myoblast amplification and loss of MyoD induced an increased propensity for self-renewal rather than progression through myogenic differentiation. The differentiation factors myogenin and MRF4 are not involved in satellite cell development or maintenance [84] but induction of myogenin is necessary and sufficient for the formation of myotubes and fibers.

### 5.2. IGF-I and calcineurin-dependent signaling

IGF-I positively regulated not only the proliferation but also the differentiation of satellite cells/myoblasts *in vitro* possibly through a calcineurin-dependent pathway. Since activated calcineurin promotes the transcription and activation of myocyte enhance factor 2 (MEF2), myogenin, and MyoD [85-87], calcineurin seems to control satellite cell differentiation and myofiber growth and maturation, all of which are involved in muscle regeneration [88, 89]. In fact, our previous study [88] showed a marked increase in the amount of calcineurin protein and the clear colocalization of calcineurin and MyoD or myogenin in many myoblasts and myotubes during muscle regeneration. In addition, we showed that the inhibition of calcineurin by cyclosporine A (CsA) induced extensive inflammation, marked fiber atrophy, and the appearance of immature myotubes in regenerating muscle compared with placebo-treated mice [88]. Several other studies indicated such defects in skeletal muscle regeneration when calcineurin was inhibited [90, 91], whereas transgenic activation

of calcineurin is known to markedly promote the remodeling of muscle fibers after damage [92, 93].

Many researchers have utilized CsA, though in different amounts, to determine the downstream modulators of calcineurin signaling. We found that intraperitoneal CsA treatment daily at 25 mg/Kg/day enhanced the expression of myostatin and Smad3 mRNA in regeneration-defective tibialis anterior muscle after an injection of bupivacaine [89]. The possibility that myostatin is a downstream mediator of calcineurin signaling has been indicated by experiments with two different transgenic mice [94]. In addition, calcineurin's pharmacological inhibition caused a decline in the transcription and activation of myogenin and MyoD during myogenic differentiation by a downregulation of MyoD expression [95]. Considering these findings, calcineurin seems to block the myostatin-Smad3 pathway to enhance the expression of myogenic differentiation factor (MyoD) during muscle regeneration *in vivo*. Using CsA treatment *in vivo*, recent evidence including that obtained by our group has also identified Id1 [87, 89], Id3 [87], and Egr-1 [87] as a possible downstream negative hypertrophic effector target of the calcineurin-NFAT (nuclear factor of activated T-cells) pathway.

FOXO (forkhead box O)-induced expression of Atrogin-1 has been shown to inhibit calcineurin activity [96]. More recently, the calcineurin variant CnA $\beta$ 1 was suggested to block the nuclear localization of the FOXO protein and the expression of several genes targeted by FOXO [the muscle ring finger-1 (MuRF1), Gadd45a, Pmaip1, and atrogin genes] in C2C12 myoblasts [93]. In addition, transgenic up-regulation of CnA $\beta$ 1 expression promotes the remodeling of cardiotoxin-treated muscle fibers [93]. In cardiomyocytes, calcineurin directly binds and dephosphorylates (inactivates) Akt; FOXO indirectly activates Akt by inhibiting calcineurin phosphatase activity [97]. In murine C2C12 myotubes, Akt was shown to antagonize calcineurin signaling by causing hyperphosphorylation of NFATc1 [60]. Interaction between CnA $\beta$ 1 and FOXO during muscle regeneration is a very attractive idea, although it has not been demonstrated in adult skeletal muscle *in vivo*.

### 5.3. Serum response factor

SRF is an ubiquitously expressed member of the MADS box transcription factor family, sharing a highly conserved DNA-binding/dimerization domain, which binds the core sequence of SRE/CArG boxes [CC (A/T)<sub>6</sub> GG] as homodimers [98]. Functional CArG boxes have been found in the cis-regulatory regions of various muscle-specific genes, such as the skeletal  $\alpha$ -actin [99], muscle creatine kinase, dystrophin, tropomyosin, and myosin light chain 1/3 genes. The majority of SRF's targets are genes involved in cell growth, migration, cytoskeletal organization, and myogenesis [100, 101]. SRF was first shown to be essential for both skeletal muscle cell growth and differentiation in experiments performed with C2C12 myogenic cells. In this model, SRF inactivation abolished MyoD and myogenin expression, preventing cell fusion in differentiated myotubes [102]. SRF also enhances the hypertrophic process in muscle fibers after mechanical overloading [103]. For example, we showed that, in mechanically overloaded muscles of rats, SRF protein is co-localized with MyoD and

myogenin in myoblast-like cells during the active differentiation phase [104]. Recent results obtained with specific SRF knock-out models, by the Cre-LoxP system, emphasize a crucial role for SRF in postnatal skeletal muscle growth and regeneration [105], by direct binding of IL-4 and IGF-I promoters *in vivo*. These lines of evidence appear to indicate that SRF modulates the differentiating process of satellite cells in adult mature muscle.

The expression and cellular localization of SRF and myocardin-related transcription factor-A (MRTF-A) appear to be regulated by several upstream factors including  $\beta$ 1-integrin, RhoA, striated muscle activators of Rho signaling (STARS) [106], and MuRF2 [107]. For instance, Lange et al. [107] demonstrated that SRF is blocked and relocalized by the nuclear translocation of MuRF2, which regulates a signaling pathway composed of titin-Nbr1-p62/SQSTM1 at the position of the sarcomere depending on mechanical activity. To date, there has been no attempt to investigate whether titin-Nbr1-p62/SQSTM1 and MuRF2 affect muscle regeneration. In addition, the mutation of SRF delineated the translocational action of MRTF-A induced *in vitro* by STARS, a muscle-specific actin-binding protein [106].

#### 5.4. Wnt-dependent signaling

Similar to Notch signaling, canonical Wnt signaling is critical for muscle repair [108-111]. The canonical Wnt signaling cascade requires soluble Wnt ligands to interact with Frizzled receptors and low-density lipoprotein receptor-related protein co-receptors (LRP). This coordination stimulates phosphorylation of Disheveled and inactivates GSK3 $\beta$ 's phosphorylation of  $\beta$ -catenin. In the nucleus, the de-phosphorylated  $\beta$ -catenin binds to T-cell factor/Lymphoid enhancer factor-1 transcription factors [112], which may directly activate Myf5 and MyoD or may upregulate MRF co-activators such as c-Jun N-terminal kinases [113, 114]. It is suggested that Notch activity presides during myoblast proliferation after which there is a temporal switch to Wnt signaling and subsequent myoblast differentiation and fusion into myotubes [108]. Inhibiting Notch (with soluble Jagged ligand or with a  $\gamma$ -secretase inhibitor) or activating Wnt (by inhibiting GSK3 $\beta$  or adding Wnt3a) decreases Myf5 expression and promotes muscle differentiation providing evidence that Notch signaling needs to be turned off and Wnt turned on for differentiation to ensue [108, 115].

This hypothesis was supported by the finding that aberrant activation of the Wnt pathway can lead to fibrogenic conversion of cells in different lineages [116-118]. In fact, Wnt signaling was shown to be enhanced in aged muscle and in myogenic progenitors exposed to aged serum [116]. To directly test the effects of Wnt on cell fate and muscle regeneration, Brack et al. [116] altered Wnt signaling *in vitro* and *in vivo*. Addition of Wnt3A protein to young serum resulted in increased myogenic-to-fibrogenic conversion of progenitors *in vitro* [116]. Conversely, the myogenic-to-fibrogenic conversion of aged serum was abrogated by Wnt inhibitors [116]. *In vivo*, the injection of Wnt3A into young regenerating muscle 1 day after injury resulted in increased connective tissue deposition and a reduction in satellite cell proliferation [116]. The authors therefore tested whether inhibiting Wnt signaling in aged muscle would reduce fibrosis and enhance muscle regeneration.

## 6. Second-stage fusion (late differentiation)

Growth and maturation of the muscle cells are achieved through a second-stage fusion, which occurs between the nascent myofibers/myotubes and myoblasts. Although many regulators of this fusion process have been revealed in recent years [119], a better understanding of the regulation is still needed. mTOR (mammalian target of rapamycin) is one of the candidates regulating the fusion. mTOR signaling regulates a wide range of biological processes, including cell growth, various types of cellular differentiation, and metabolism [120, 121]. mTOR assembles two biochemically and functionally distinct protein complexes, mTORC1 (mTOR complex 1) and mTORC2, which are sensitive and insensitive to rapamycin, respectively [120]. Rapamycin-sensitive mTORC1 signaling has emerged as a key regulator of skeletal muscle differentiation and remodeling. Rapamycin inhibits myoblast differentiation *in vitro* [122, 123], compensatory myofiber hypertrophy *in vivo*, and regrowth of myofibers after atrophy [124]. The regulation of skeletal myocyte differentiation by mTORC1 occurs at two stages via distinct mechanisms. mTORC1 controls the initiation of myoblast differentiation by regulating IGF-II expression [123], whereas late-stage myocyte fusion leading to myotube maturation is regulated by mTORC1 through a yet to be identified secreted factor [125]. More recent findings pointed out that the fusion factor targeting mTORC1 is follistatin during the late differentiation phase. Sun et al. [126] have found that, in C2C12 cells differentiating for 24-72h, miR-1 luciferase (enhancer) activity was markedly downregulated after treatment with rapamycin but not wortmannin (PI3-K inhibitor) or SB203580 (MAPK inhibitor). In addition, rapamycin increased the amount of histone deacetylase 4 (HDAC4) protein and reduced follistatin mRNA and MyoD protein levels in C2C12 and C3H10T1/2 cells. Furthermore, daily administration of trichostatin A and a single dose of adenovirus expressing follistatin rescued the defective muscle regeneration caused by treatment with rapamycin. Sun et al. [126] proposed the intriguing hypothesis that mTOR-miR-1 promotes myocyte fusion by recruiting HDAC4-follistatin during myoblast differentiation *in vitro* and skeletal muscle regeneration *in vivo*.

## 7. Satellite cell self-renewal

A hallmark of stem cells is their ability to self-renew. In skeletal muscle, asymmetric cell division takes place in a subset of the satellite cell population to generate a self-renewing progenitor and hyperplastic daughter cell which later contributes to *de novo* muscle formation [127]. Several extrinsic pathways have been implicated in mediating this phenomenon [108, 127, 128]. One family of candidate peptides is the Wnt family of signaling molecules which consists of over 19 cysteine-rich secreted glycoproteins that in part bind the Frizzled (Fzd) receptors [129].

In a non-canonical Wnt cascade, Wnt7a has been characterized for its role as the extracellular ligand mediating asymmetric cell division which is thought to be the mechanism by which satellite cells are able to self-renew [128]. Lineage tracing of satellite cell populations indicates ~90% of cells to have at some point expressed Myf5 (Pax7+Myf5+) [127]. The Myf5+ cells have a reduced potential to self-renew as the majority undergo

symmetrical cell divisions and later contribute to muscle syncytia [127]. The remaining ~10% of satellite cells divide asymmetrically and give rise to Pax7+Myf5<sup>-</sup> as well as Pax7+Myf5<sup>+</sup> progeny thereby maintaining the stem cell pool of muscle progenitors [127]. The capacity of Pax7+Myf5<sup>-</sup> cells to self-renew is explained by expression of the Wnt receptor Fzd7 on these cells but not on Pax7+Myf5<sup>+</sup> cells, thus allowing induction of asymmetrical cell division via Wnt7a-induced signaling [128]. Importantly, stimulation of satellite cells with Wnt7a leads to an increase in the symmetrical expansion of satellite cells, while muscle from Wnt7a knockout mice displays a dramatic reduction in satellite cell numbers following regeneration [128].

The Notch inhibitor, Numb is also asymmetrically expressed on the activated satellite cells and may regulate cell fate choices by promoting progression down the myogenic lineage [130]. Self renewal may also occur through symmetrical division in which both daughter cells maintain stem-cell properties [131, 132]. Cells that do not express MyoD but continue to express Pax7 are suggested to be refrained from self-renewal [133].

## 8. Other regulators of the muscle regenerating process

### 8.1. Myostatin and TGF- $\beta$

The TGF- $\beta$  superfamily plays a crucial role in normal physiology and pathogenesis in a number of tissues. Myostatin was first discovered during screening for novel members of the TGF- $\beta$  superfamily, and shown to be a potent negative regulator of muscle growth [134]. Like other TGF- $\beta$  family members, myostatin is synthesized as a precursor protein that is cleaved by furin proteases to generate the active C-terminal dimer. When produced in Chinese hamster ovary cells, the C-terminal dimer remains bound to the N-terminal propeptide, which remains in a latent, inactive state [135]. Most, if not all, of the myostatin protein that circulates in blood also appears to exist in an inactive complex with a variety of proteins, including the propeptide [136]. Myostatin binds to and signals through a combination of Activin IIA/B receptors on the cell membrane, but has higher affinity for ActRIIB. On binding to ActRIIB, myostatin forms a complex with a second surface type I receptor, either activin receptor-like kinase (ALK4 or ActRIB) or ALK5 to stimulate the phosphorylation of receptor Smad and the Smad2/3 transcription factors in the cytoplasm. This leads to the assembly of Smad2/3 with Smad4 to form a heterodimer that is able to translocate to the nucleus and activate the transcription of target genes [137].

Studies indicate that myostatin inhibits the activation, differentiation, and self-renewal of satellite cells [138-140] and the expression of the muscle regulatory factors crucial for the regeneration and differentiation of myofibers [138, 141]. One of the known downstream targets of Smad signaling is MyoD. Interestingly, myostatin downregulates MyoD expression in an NF- $\kappa$ B-independent manner [142]. Myostatin also inhibits Pax3 expression, which is possibly an upstream target of MyoD [142]. Recently, it was found that FOXO1 and Smad synergistically increase the expression of myostatin mRNA and its promoter activity

in C2C12 myotubes [95]. Taken together, myostatin-mediated signaling activates FOXO, and this leads to the expression of ubiquitin ligases.


TGF- $\beta$ 1 is expressed during myogenesis, and its spatial and temporal expression in the developing connective tissue is correlated with the fiber-type composition of the surrounding myotubes. Myotubes formed before the expression of TGF- $\beta$ 1 develop into slow fibers, whereas fast fibers form when myoblasts are adjacent to connective tissue expressing TGF- $\beta$ 1 [143]. TGF- $\beta$ 1 has been shown to inhibit the differentiation of fetal myoblasts but does not affect embryonic myoblasts [144]. In mature adult muscle, TGF- $\beta$  negatively affects skeletal muscle regeneration by inhibiting satellite cell proliferation, myoblast fusion, and expression of some muscle specific-genes [145]. Furthermore, TGF- $\beta$ 1 induced the transformation of myogenic cells into fibrotic cells after injury [146].

TGF- $\beta$ 1, a potent regulator of tissue wound healing and fibrosis, is physiologically upregulated in regenerating skeletal muscle after injury and exercise and is thought to participate in a transient inflammatory response to muscle damage [147, 148]. Persistent exposure to the inflammatory response leads to an altered extracellular matrix and increased levels of growth factors and cytokines, including TGF- $\beta$ 1, which contribute to the formation of fibrotic tissue [147, 148]. Increased levels of TGF- $\beta$ 1 inhibit satellite cell activation and impair myocyte differentiation [145, 149]. Figure 1 summarizes the calcineurin-, myostatin-, and Akt-dependent signaling in muscle regeneration.

## 8.2. TNF- $\alpha$ signaling

TNF- $\alpha$  has long been viewed as the quintessential proinflammatory cytokine, capable of classical activation of macrophages to the M1 phenotype, and thereby inducing the production of other proinflammatory, Th1 cytokines. Following muscle injury, the early invading neutrophil and macrophage populations express TNF- $\alpha$  [152], suggesting that the cytokine may contribute to the early inflammatory stages that precede muscle regeneration. TNF- $\alpha$  levels in muscle following acute injury peak at 24h postinjury, which indicates that TNF- $\alpha$  production is most tightly coupled with the Th1 inflammatory response in injured muscle [153]. Because findings show that TNF- $\alpha$  induces iNOS expression in myeloid cells and that myeloid cell-derived NO can cause muscle fiber damage early on, Th1 inflammatory cells have been associated with muscle damage. However, TNF- $\alpha$  levels remain elevated for nearly 2 weeks following acute injury, indicating that TNF- $\alpha$  may also modulate the regenerative process [153]. Intriguingly, the expression of TNF- $\alpha$  receptors by muscle cells themselves is elevated as a later consequence of injury, during the regenerative process, and enables TNF- $\alpha$  to act directly on muscle cells to modulate their proliferation and differentiation [152].

Numerous experimental observations indicate that TNF- $\alpha$  acts directly on muscle cells in affecting muscle regeneration. For example, TNF- $\alpha$  null mutants and TNF- $\alpha$  receptor mutants show lower levels of MyoD and MEF2 expression than wild-type controls following acute injury [153, 154]. The application of exogenous TNF- $\alpha$  to myoblasts *in vitro*



**Figure 1.** Schematic diagram of calcineurin-, myostatin-, and Akt-dependent signaling in muscle regeneration. Myostatin acts through activin receptor IIB (ActRIIB). The ALK4/5 heterodimer activates Smad2/3 with blocking of MyoD transactivation in an autoregulatory feedback loop. In addition, Smad3 sequesters MyoD in the cytoplasm to prevent it from entering the nucleus and activating the stem cell population. In proliferating myoblasts, this pathway arrests cell proliferation and differentiation. Moreover, recent findings [150, 151] suggest that the myostatin-Smad pathway inhibits protein synthesis probably by blocking the functional role of Akt. Damage the muscle fiber membranes after treatment with myotoxin elicits an increase in intracellular Ca<sup>2+</sup> levels via the influx of Ca<sup>2+</sup> from the extracellular space. Binding of the Ca<sup>2+</sup>/CaM complex to the calcineurin regulatory subunit leads to its activation. Activated calcineurin dephosphorylates a range of transcription factors (including MEF2 and NFAT). Activated calcineurin inhibits the functional role of Egr-1 and Smad2/3 [87, 89], and promotes myogenic differentiation. Calcineurin signaling is markedly inhibited by myostatin [94] and FOXO [96, 97]. IGF-I produced by the regenerating muscle activates PI3-K-Akt-mTOR signaling resulting in a positive protein balance. One part of mTOR (mTORC1) enhances myotube differentiation at later stages probably through the induction of follistatin expression. CaM; calmodulin, IRS-1; insulin receptor substrate-1


increases their proliferation, and inhibited the process of early differentiation to terminal differentiation [155-157]. Experiments *in vivo* using a lung-specific TNF- $\alpha$  transgene also showed a differentiation-inhibiting role [158]. These TNF- $\alpha$  abundant mice exhibited attenuated expression of developmental myosin heavy chain (MHC) in reloaded soleus muscle after hindlimb suspension [158]. TNF- $\alpha$  affects several intracellular signaling pathways leading to the activation of NF- $\kappa$ B, caspase 8, and stress-induced factors like c-Jun N-terminal kinase (JNK) and p38 MAPK [159]. Activation of NF- $\kappa$ B can inhibit myogenesis

through several processes. NF- $\kappa$ B can promote the expression and stability of cyclin D1 in muscle [155], leading to increased cell proliferation and inhibition of differentiation. Furthermore, NF- $\kappa$ B can cause destabilization of MyoD mRNA and degradation of MyoD protein [155, 156]. The role of JNK in the effect of TNF- $\alpha$  on myogenesis has been less investigated. A recent study suggested that activation of JNK by TNF- $\alpha$  blocks IGF-I signaling necessary for the differentiation of myoblasts [160].

TNF- $\alpha$  can activate signaling through other pathways independent of NF- $\kappa$ B to promote muscle differentiation. Both IL-1 and TNF- $\alpha$  can activate p38 kinase [161], promoting the differentiation. In particular, inhibition of p38 in skeletal muscle cells *in vitro* inhibits myocytes from fusing to form myotubes and reduces the expression of MEF2, myogenin, and myosin light chain kinase [162], all of which indicate that p38 activation can promote muscle differentiation. Furthermore, p38 activation can also increase the activity of MyoD [162, 163]. The ability of p38 to promote myogenesis relies, in part, on its ability to phosphorylate and increase the transcriptional activity of MEF2 [162, 164]. In contrast, p38 activation can also inhibit myogenesis by the phosphorylation of other MyoD family members (MRF4). The elevated expression and activity of p38 late in muscle differentiation leads to increased MRF4 phosphorylation and, as a consequence, a decline in desmin and skeletal  $\alpha$ -actin expression [165]. In fact, overexpression of MRF4 in a transgenic mouse line caused defective muscle regeneration following injury [166]. Therefore, TNF- $\alpha$ -dependent signaling regulates various aspects of the muscle regenerating process (immune response, and proliferation and differentiation of satellite cells) through different downstream mediators (NF- $\kappa$ B, JNK, and p38) [Figure 2].

### 8.3. TWEAK

TNF-like weak inducer of apoptosis (TWEAK) is a pro-inflammatory cytokine belonging to the TNF superfamily of ligands. Initially synthesized as a type II transmembrane protein, TWEAK is cleaved to its soluble form, and signals as a trimerized molecule [167]. Generally, TWEAK signaling occurs through binding to Fn14, a type I transmembrane receptor belonging to the TNF receptor superfamily. TWEAK has been found to promote the regeneration and growth of myofibers after injury [168-170]. Dogra et al. [168] reported that TWEAK inhibits the differentiation of cultured C2C12 or primary myoblasts into multinucleated myotubes. More recently, a transgenic model of TWEAK also suggested a differentiation-promoting role in muscle regeneration *in vivo*. In fact, mRNA levels of TNF- $\alpha$ , IL-6 and CCL-2 and protein levels of embryonic MHC were significantly reduced in cardiotoxin (CTX)-injected TA muscle of TWEAK-KO mice compared to that of wild-type mice [171]. In addition, these parameters were found to be significantly increased in regenerating TA muscle of TWEAK-Tg mice compared to that of control mice. Since such a modulation of the TWEAK gene caused no apparent differences in levels of phospho-Akt and phospho p38MAPK in the regenerating muscle among each mouse model, TWEAK seems to function independently of Akt- and p38-linked signaling [171]. Intriguingly, electromobility shift assay by Mittal et al. [171] indicated the possibility of TWEAK-NF- $\kappa$ B signaling, although further descriptive analysis needs to be done.



**Figure 2.** The functional role of TNF- $\alpha$  signaling in the regenerating muscle. HGF and nNOS co-ordinate the switch from quiescence to activation in satellite cells. IGF-I enhances the proliferation of satellite cells via a MAPK-dependent pathway. IGF-I also promotes myogenic differentiation via p21 and myogenin. In regenerating muscle after treatment with myotoxin, the differentiating myotubes seem to be fused together and/or incorporated into the existing muscle fibers. TNF- $\alpha$ , which is produced by the damaged muscle and macrophages, stimulates TNFR. TNFR activates NF- $\kappa$ B-signaling, in turn cyclin D1 activate the proliferation, but not differentiation, of satellite cells. In addition, TNF- $\alpha$  activates p38-dependent signaling leading to the differentiation of myoblasts.

#### 8.4. MicroRNAs

The human genome contains thousands of non-coding RNAs, the best-studied class of which are microRNAs (miRNAs)[172], which regulate gene expression at the transcriptional and post-transcriptional levels. miRNAs suppress gene expression through their complementarity to the sequence of one or more RNAs, usually at a site in the 3' untranslated region. The formation of a miRNA-target complex results either in inhibition of protein translation or in degradation of the mRNA transcript through a process similar to RNA interference [173]. There is no doubt that the formation, maintenance, and physiological and pathophysiological responses of skeletal muscles, with all their complex regulatory circuits, are subject to regulation by non-coding RNAs.

Many miRNAs are expressed in skeletal and cardiac muscle. Some of them are found specifically, or at least are highly concentrated, in skeletal and/or cardiac muscle, suggesting

specific roles in myogenesis [174]. The expression of the muscle-specific miRNAs miR-1, miR-133, miR-206, and miR-208 seems to be under the control of a core muscle transcriptional network, which involves the pleiotropic SRF, MyoD, and the bHLH transcription factor Twist in cooperation with MEF2 [175-177]. Chromatin immunoprecipitation followed by a microarray analysis indicated that MyoD and myogenin bind sequences upstream of miR-1 and miR-133 [176]. miR-133a increases myoblast proliferation, via its repression of SRF [178], while miR-1 stimulates myoblast differentiation via its inhibition of histone deacetylase 4 (HDAC4) [178]. In addition, MyoD has been demonstrated to utilize miRNAs, including miR-1 and miR-206, to suppress downstream gene expression [178, 179]. More recently, Hirai et al. [180] have demonstrated that miR-1 and miR-206 bind to two miR-1/miR-206-binding sequences within the Pax3-3'UTR and suppress Pax3 expression. Since Pax3 expression increases cell survival and suppresses myogenic differentiation in myoblasts, down-regulation of Pax3 has been shown to elicit proper myogenic differentiation along with an increase in apoptosis [180]. An analogous role was described for the regulation of Pax7, which is repressed by miR-1 and miR-206 [178, 181]. In contrast, miR-221 and miR-222 are downregulated during the transition from proliferation to differentiation [182]. Decreases in these miRNAs are associated with increased expression of the cell cycle inhibitor p27. Overexpression of miR-221 and miR-222 in differentiating myotubes delays cell cycle withdrawal and differentiation, a response associated with a reduction in sarcomeric protein [182].

## 9. Conclusions and perspectives

In normal, skeletal muscle possesses a robust capacity to repair itself, the ability to augment and enhance this process would significantly advance the treatment of congenital muscle disorders and severe muscle trauma for which, even with the best of present-day treatments, physical handicap or amputation are the most likely outcomes. Sarcopenia seems to include the defect of muscle regeneration probably due to the repetitive muscular damage [8-10]. Currently available data show that resistance training combined with amino acid-containing supplements would be the best way to prevent age-related muscle wasting and weakness. Therefore, for these endogenous repair therapies to advance, it is essential that an understanding exists of the biochemical, cellular and mechanical cues that promote skeletal muscle repair.

### Author details

Kunihiro Sakuma

*Corresponding Author*

*Research Center for Physical Fitness, Sports and Health, Toyohashi University of Technology,  
Tenpaku-cho, Toyohashi, Japan*

Akihiko Yamaguchi

*School of Dentistry, Health Sciences University of Hokkaido, Kanazawa, Ishikari-Tobetsu,  
Hokkaido, Japan*

## Acknowledgement

This work was supported by a research Grant-in-Aid for Scientific Research C (No. 23500578) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

## 10. References

- [1] Lexell J (1993) Ageing and human muscle: observations from Sweden. *Can. J. Appl. Physiol.* 18: 2-18.
- [2] Roubenoff R, Hughes VA (2000) Sarcopenia: current concepts. *J. Gerontol. A Biol. Sci. Med. Sci.* 55: M716-M724.
- [3] Scott D, Blizzard L, Fell J, Jones G (2010) The epidemiology of sarcopenia in community living older adults: what role does lifestyle play? *J. Cachex. Sarcopenia Muscle* 2: 125-134.
- [4] Sakuma K, Yamaguchi A (2012) Sarcopenia and age-related endocrine function. *Int. J. Endocrinol.* 2012: Article ID 127362 (in press).
- [5] Sakuma K, Yamaguchi A (2011) Sarcopenia: Molecular mechanisms and current therapeutic strategy. In: Perloft JW, Wong AH, Eds. *Cell Aging*. Nova Science Publishers, NY, pp 93-152.
- [6] Sakuma K, Akiho M, Nakashima H, Akima H, Yasuhara M (2008) Age-related reductions in expression of serum response factor and myocardin-related transcription factor A in mouse skeletal muscles. *Biochim. Biophys. Acta Mol. Basis Dis.* 1782: 453-461.
- [7] Sakuma K, Yamaguchi A (2010) Molecular mechanisms in aging and current strategies to counteract sarcopenia. *Curr. Aging Sci.* 3: 90-101.
- [8] Conboy IM, Conboy MJ, Smythe GM, Rando TA (2003) Notch-mediated restoration of regenerative potential to aged muscle. *Science* 302: 1575-1577.
- [9] Conboy IM, Conboy MJ, Wagners AJ, Girma ER, Weissman IL, Rando TA (2005) Rejuvenation of aged progenitor cells by exposure to a young systemic environment. *Nature* 433: 760-764.
- [10] Carlson ME, Hsu M, Conboy IM (2008) Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. *Nature*. 454: 528-532.
- [11] Stoick-Cooper CL, Moon RT, Weidinger G (2007) Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine. *Genes Dev.* 21: 1292-1315.
- [12] Mauro A (1961) Satellite cell of skeletal muscle fibers. *J. Biophys. Biochem. Cytol.* 9: 493-495.
- [13] Kuang S, Rudnicki MA (2008) The emerging biology of satellite cells and their therapeutic potential. *Trends Mol. Med.* 14: 82-91.
- [14] Kuang S, Gillespie MA, Rudnicki MA (2008) Niche regulation of muscle satellite cell self-renewal and differentiation. *Cell Stem Cell* 2: 22-31.
- [15] Peterson JM, Guttridge DC (2008) Skeletal muscle diseases, inflammation, and NF-kappaB signaling: Insights and opportunities for therapeutic intervention. *Int. Rev. Immunol.* 27: 375-387.

- [16] Mozzetta C, Minetti G, Puri PL (2009) Regenerative pharmacology in the treatment of genetic diseases: The paradigm of muscular dystrophy. *Int. J. Biochem. Cell Biol.* 41: 701-710.
- [17] Al-Shanti N, Stewart CE (2009) Ca<sup>2+</sup>/calmodulin-dependent transcriptional pathways: Potential mediators of skeletal muscle growth and development. *Biol. Rev. Camb. Philos. Soc.* 84: 637-652.
- [18] Mantovani A, Sica A, Locati M (2007) New vistas on macrophage differentiation and activation. *Eur. J. Immunol.* 37: 14-16.
- [19] Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G (2000) Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. *J. Leukoc. Biol.* 67: 97-103.
- [20] St Pierre BA, Tidball JG (1994) Differential response of macrophage subpopulations to soleus muscle reloading after rat hindlimb suspension. *J. Appl. Physiol.* 77: 290-297.
- [21] Arnold L, Henry A, Poron F, Baba-Amer Y, Van Rooijen, Plonquet A, Gherardi RK, Chazaud B (2007) Inflammatory monocytes recruited after skeletal muscle injury switch into anti-inflammatory macrophages to support myogenesis. *J. Exp. Med.* 204: 1057-1069.
- [22] Bryer SC, Fantuzzi G, Van Rooijen N, Koh TJ. Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. *J. Immunol.* 180: 1179-1188.
- [23] Koh TJ, Bryer SC, Pucci AM, Sisson TH (2005) Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration. *Am. J. Physiol. Cell Physiol.* 289: C217-C223.
- [24] Musaró A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. *Nat. Genet.* 27: 195-200.
- [25] Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, Battistini L, Rosenthal N, Molinaro M, Musaró A (2007) Local expression of IGF-I accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. *FASEB J.* 21: 1393-1402.
- [26] Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, Bianchi ME (2007) Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. *J. Cell Biol.* 179: 33-40.
- [27] Hawke TJ, Garry DJ (2001) Myogenic satellite cells: Physiology and molecular biology. *J. Appl. Physiol.* 91: 534-551.
- [28] Bischoff R (1986) A satellite cell mitogen from crushed adult muscle. *Dev. Biol.* 115: 140-147.
- [29] Bischoff R (1990) Cell cycle commitment of rat muscle satellite cells. *J. Cell Biol.* 111: 201-207.
- [30] Bischoff R (1986) Proliferation of muscle satellite cell on intact myofibers in culture. *Dev. Biol.* 115: 129-139.
- [31] Johnson SE, Allen RE (1995) Activation of skeletal satellite cells and the role of fibroblast growth-factor receptors. *Exp. Cell Res.* 219: 449-453.

- [32] Allen RE, Temm-Grove CJ, Sheehan SM, Rice GM (1997) Skeletal muscle satellite cell cultures. *Methods in Cell Biol.* 52: 155-176.
- [33] Tatsumi R, Anderson JE, Nevoret CJ, Halevy O, Allen RE (1998) HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. *Dev. Biol.* 194: 114-128.
- [34] Anderson JE (2000) A role for nitric oxide in muscle repair: NO-mediated satellite cell activation. *Mol. Biol. Cell* 11: 1859-1874.
- [35] Tatsumi R, Liu X, Pulido A, Morales M, Sakata T, Dial S, Hattori A, Ikeuchi Y, Allen RE (2006) Satellite cell activation in stretched skeletal muscle and the role of nitric oxide and hepatocyte growth factor. *Am. J. Physiol. Cell Physiol.* 290: C1487-C1494.
- [36] Miller KJ, Thaloor D, Matteson S, Pavlath GK (2000) Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle. *Am. J. Physiol. Cell Physiol.* 278: C174-C181.
- [37] Yamada M, Tatsumi R, Yamanouchi K, Hosoyama T, Shiratsuchi S, Sato A, Mizunoya W, Ikeuchi Y, Furuse M, Allen RE (2010) High concentrations of HGF inhibit skeletal muscle satellite cell proliferation in vitro by inducing expression of myostatin: A possible mechanism for reestablishing satellite cell quiescence in vivo. *Am. J. Physiol. Cell Physiol.* 298: C465-C476.
- [38] Brenman JE, Chao DS, Xia H, Aldape K, Bretz DS (1995) Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. *Cell* 82: 743-752.
- [39] Tidball JG, Lavergne E, Lau KS, Spencer MJ, Stull JT, Wehling M (1998) Mechanical loading regulates NOS expression and activity in developing and adult skeletal muscle. *Am. J. Physiol. Cell Physiol.* 275: C260-C266.
- [40] Pisconti A, Brunelli S, Di Padova M, De Palma C, Deponti D, Baesso S, Sartorelli V, Cossu G, Clementi E (2006) Follistatin induction by nitric oxide through cyclic GMP: A tightly regulated signaling pathway that controls myoblast fusion. *J. Cell Biol.* 172: 233-244.
- [41] Broholm C, Mortensen OH, Nielsen S, Akerstrom T, Zankari A, Dahl B, Pedersen BK (2008) Exercise induces expression of leukemia inhibitory factor in human skeletal muscle. *J. Physiol.* 586: 2195-2201.
- [42] Metcalf D (2003) The unsolved enigmas of leukemia inhibitory factor. *Stem Cells* 21: 5-14.
- [43] Hinds MG, Mauer T, Zhang JG, Nicola NA, Norton RS (1997) Resonance assignments, secondary structure and topology of leukemia inhibitory factor in solution. *J. Biomed. NMR.* 9: 113-126.
- [44] Schmelzer CH, Burton LE, Tamony CM (1990) Purification and partial characterization of recombinant human differentiation-stimulating factor. *Protein Expr. Purif.* 1: 54-62.
- [45] Kami K, Semba E (1998) Localization of leukemia inhibitory factor and interleukin-6 messenger ribonucleic acids in regenerating rat skeletal muscle. *Muscle Nerve* 21: 819-822.
- [46] Sakuma K, Watanabe K, Sano M, Uramoto I, Totsuka T (2000) Differential adaptation of growth and differentiation factor 8/myostatin, fibroblast growth factor 6 and leukemia

- inhibitory factor in overloaded, regenerating, and denervated rat muscles. *Biochim. Biophys. Acta Mol. Cell Res.* 1497: 77-88.
- [47] Gregorevic P, Williams DA, Lynch GS (2002) Effects of leukemia inhibitory factor on rat skeletal muscles are modulated by clenbuterol. *Muscle Nerve* 25: 194-201
- [48] Kurek JB, Bower JJ, Romanella M, Koentgen F, Murphy M, Austin L (1997) The role of leukemia inhibitory factor in skeletal muscle regeneration. *Muscle Nerve* 20: 815-822.
- [49] Barnard W, Bower J, Brown MA, Murphy M, Austin L (1994) Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: Injured muscle expresses LIF mRNA. *J. Neurol. Sci.* 123: 108-113.
- [50] Austin L, Burgess AW (1991) Stimulation of myoblast proliferation in culture by leukaemia inhibitory factor and other cytokines. *J. Neurol. Sci.* 101: 193-197.
- [51] Diao Y, Wang X, Wu Z (2009) SOCS1, SOCS3, and PIAS1 promote myogenic differentiation by inhibiting the leukemia inhibitory factor-induced JAK1/STAT1/STAT3 pathway. *Mol. Cell. Biol.* 29: 5084-5093.
- [52] Sun L, Ma K, Wang H, Xiao F, Gao Y, Zhang W, Wang K, Gao X, Ip N, Wu Z (2007) JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts. *J. Cell Biol.* 179: 129-138.
- [53] Kami K, Morikawa Y, Sekimoto M, Senba E (2000) Gene expression of receptors for IL-6, LIF, and CNTF in regenerating skeletal muscles. *J. Histochem. Cytochem.* 48: 1203-1213.
- [54] Austin L, Bower J, Kurek J, Vakakis N (1992) Effects of leukaemia inhibitory factor and other cytokines on murine and human myoblast proliferation. *J. Neurol. Sci.* 112: 185-191.
- [55] White JD, Davies M, Grounds MD (2001) Leukemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: Combined in vivo and in vitro studies in postnatal skeletal muscle. *Cell Tissue Res.* 306: 129-141.
- [56] Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, Kishimoto T, Yamauchi-Takahara K (2001) Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/akt phosphorylation and Bcl-xL/caspase-3 interaction. *Circulation* 103: 555-561.
- [57] Hunt LC, Tudor EM, White JD (2010) Leukemia inhibitory factor-dependent increase in myoblast cell number is associated with phosphatidylinositol 3-kinase-mediated inhibition of apoptosis and not mitosis. *Exp. Cell Res.* 316: 1002-1009.
- [58] Adams GR, McCue SA (1998) Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. *J. Appl. Physiol.* 84: 1716-1722.
- [59] Chakravarthy MV, Davis BS, Booth FW (2000) IGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle. *J. Appl. Physiol.* 89: 1365-1379.
- [60] Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ (2001) Mediation of IGF-I-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. *Nat. Cell Biol.* 3: 1009-1013.
- [61] Devol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ (1990) Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. *Am. J. Physiol.* 259: E89-E95.
- [62] Sakuma K, Watanabe K, Totsuka T, Uramoto I, Sano M, Sakamoto K (1998) Differential adaptations of insulin-like growth factor-I, basic fibroblast growth factor, and leukemia

- inhibitory factor in the plantaris muscle of rats by mechanical overloading: An immunohistochemical study. *Acta Neuropathol.* 95: 123-30.
- [63] Philippou A, Maridaki M, Halapas A, Koutsilieris M (2007) The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. *In Vivo* 21: 45-54.
- [64] Clemmons DR (2009) Role of IGF-I in skeletal muscle mass maintenance. *Trends Endocrinol. Metabol.* 20: 349-356.
- [65] Adi S, Bin-Abbas B, Wu NY, Rosenthal SM (2002) Early stimulation and late inhibition of extracellular signal-regulated kinase 1/2 phosphorylation by IGF-I: A potential mechanism mediating the switch in IGF-I action on skeletal muscle cell differentiation. *Endocrinology* 143: 511-516.
- [66] Milasincic DJ, Calera MR, Farmer SR, Pilch PF (1996) Stimulation of C2C12 myoblast growth by basic fibroblast growth factor and insulin-like growth factor 1 can occur via mitogen-activated protein kinase-dependent and -independent pathways. *Mol. Cell Biol.* 16: 5964-5973.
- [67] Haq S, Kilter H, Michael A, Tao J, O'Leary E, Sun XM, Walters B, Bhattacharya K, Chen X, Cui L, Andreucci M, Rosenzweig A, Guerrero JL, Patten R, Liao R, Molkentin J, Picard M, Bonventre JV, Force T (2003) Deletion of cytosolic phospholipase A2 promotes striated muscle growth. *Nat. Med.* 9: 944-951.
- [68] Tiffin N, Adi S, Stokoe D, Wu NY, Rosenthal SM (2004) Akt phosphorylation is not sufficient for insulin-like growth factor-stimulated myogenin expression but must be accompanied by down-regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase phosphorylation. *Endocrinology* 145: 4991-4996.
- [69] Czifra G, Tóth IB, Marincsák R, Juhász I, Kovács I, Acs P, Kovács L, Blumberg PM, and Bíró T (2006) Insulin-like growth factor-I-coupled mitogenic signaling in primary cultured human skeletal muscle cells and in C2C12 myoblasts. *Cell. Signal.* 18: 1461-1472.
- [70] Conboy IM, Rando TA (2002) The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. *Dev. Cell.* 3: 397-409.
- [71] Kitzmann M, Bonniou A, Duret C, Vernus B, Barro M, Laodj-Chevivesse D, Verdi JM, Carnac G (2006) Inhibition of notch signaling induces myotube hypertrophy by recruiting a subpopulation of reserve cells. *J. Cell. Physiol.* 208: 538-548.
- [72] Buas M, Kabak S, Kadesch T (2009) Inhibition of myogenesis by Notch: Evidence for multiple pathways. *J. Cell. Physiol.* 218: 84-93.
- [73] Ono Y, Gnocchi VF, Zammit PS, Nagatomi R (2009) Presenilin-1 acts via Id1 to regulate the function of muscle satellite cells in a gamma-secretase-independent manner. *J. Cell. Sci.* 122: 4427-4438.
- [74] Vasyutina E, Lenhard DC, Wende H, Erdmann B, Epstein JA, Birchmeier C (2007) RBP-J (Rbpsi) is essential to maintain muscle progenitor cells and to generate satellite cells. *Proc. Natl. Acad. Sci. USA.* 104: 4443-4448.
- [75] Carlson ME, Conboy MJ, Hsu M, Barchas L, Jeong J, Agrawal A, Mikels AJ, Agrawal S, Schaffer DV, Conboy IM (2009) *Aging Cell* 8: 676-689.
- [76] Bellavia D, Checquolo S, Campese AF, Felli MP, Gulino A, Screpanti I (2008) Notch3: From subtle structural differences to functional diversity. *Oncogene* 27: 5092-5098.

- [77] Kitamoto T, Hanaoka K (2010) Notch3 null mutation in mice causes muscle hyperplasia by repetitive muscle regeneration. *Stem Cells* 28: 2205-2216.
- [78] Kuang S, Charge SB, Seale O, Huh M, Rudnicki MA (2006) Distinct roles for Pax7 and Pax3 in adult regenerative myogenesis. *J. Cell Biol.* 172: 103-113.
- [79] Zammit PS, Relaix F, Nagata Y, Ruiz AP, Collins CA, Partridge TA, Beauchamp JR (2006) Pax7 and myogenic progression in skeletal muscle satellite cells. *J. Cell. Sci.* 119: 1824-1832.
- [80] Olguin HC, Yang Z, Tapscott SJ, Olwin BB (2007) Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination. *J. Cell Biol.* 177: 769-779.
- [81] Sabourin LA, Girgis-Gabardo A, Seale P, Asakura A, Rudnicki MA (1999) Reduced differentiation potential of primary MyoD<sup>-/-</sup> myogenic cells derived from adult skeletal muscle. *J. Cell Biol.* 144: 631-643.
- [82] Cornelison DD, Olwin BB, Rudnicki MA, Wold BJ (2000) MyoD<sup>(-/-)</sup> satellite cells in single-fiber culture are differentiation defective and MRF4 deficient. *Dev. Biol.* 224: 122-137.
- [83] Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA (1996) MyoD is required for myogenic stem cell function in adult skeletal muscle. *Genes Dev.* 10: 1173-1183.
- [84] Gayraud-Morel B, Chretien F, Flamant P, Gomes D, and Zammit PS, Tajbakhsh A (2007) A role for the myogenic determination gene Myf5 in adult regenerative myogenesis. *Dev. Biol.* 312: 13-28.
- [85] Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD (2000) A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. *Mol. Cell. Biol.* 20: 6600–6611.
- [86] Friday BB, Horsley V, Pavlath GK (2000) Calcineurin activity is required for the initiation of skeletal muscle differentiation. *J. Cell Biol.* 149: 657–666.
- [87] Friday BB, Mitchell PO, Kegley KM, Pavlath GK (2003) Calcineurin initiates skeletal muscle differentiation by activating MEF2 and MyoD. *Differentiation* 71: 217–227.
- [88] Sakuma K, Nishikawa J, Nakao R, Watanabe K, Totsuka T, Nakano H, Sano M, Yasuhara M (2003) Calcineurin is a potent regulator for skeletal muscle regeneration by association with NFATc1 and GATA-2. *Acta Neuropathol.* 105: 271-280.
- [89] Sakuma K, Nakao R, Aoi W, Inashima S, Fujikawa T, Hirata M, Sano M, Yasuhara M (2005) Cyclosporin A treatment upregulates Id1 and Smad3 expression and delays skeletal muscle regeneration. *Acta Neuropathol.* 110: 269-280.
- [90] Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK (1998) Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. *Mol. Biol. Cell* 9: 2905-2916.
- [91] Koulmann N, Sanchez B, N'Guessan, Chapot R, Serrurier B, Peinnequin A, Ventura-Clapier R, Bigard, X (2006) The responsiveness of regenerated soleus muscle to pharmacological calcineurin inhibition. *J. Cell. Physiol.* 208: 116-122.
- [92] Stupka N, Schertzer JD, Bassel-Duby R, Olson EN, Lynch GS (2007) Calcineurin- $\text{A}\alpha$  activation enhances the structure and function of regenerating muscles after myotoxic injury. *Am. J. Physiol.* 293: R686–R694.

- [93] Lara-Pezzi E, Winn N, Paul A McCullagh K, Slominsky E, Santini MP, Mourkioti F, Sarathchandra P, Fukushima S, Suzuki K, Rosenthal N (2007) A naturally occurring calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration. *J. Cell Biol.* 179: 1205-1218.
- [94] Michel RN, Chin ER, Chakkalakal JV, Eibl JK, Jasmin BJ (2007) Ca<sup>2+</sup>/calmodulin-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression. *Appl. Physiol. Nutr. Metab.* 32: 921-929.
- [95] Allen DL, Unterman TG (2007) Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. *Am. J. Physiol. Cell Physiol.* 292: C188-C199.
- [96] Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C (2004) Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. *J. Clin. Invest.* 114: 1058-1071.
- [97] Ni YG, Wang N, Cao DJ, Sachan N, Morris DJ, Gerard RD, Kuro-O M, Rothermel BA, Hill JA (2007) FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. *Proc. Natl. Acad. Sci. USA.* 104: 20517-20522.
- [98] Treisman R (1987) Identification and purification of a polypeptide that binds to the c-fos serum response element. *EMBO J.* 6: 2711-2717.
- [99] Muscat GE, Gustafson TA, Kedes L (1988) A common factor regulates skeletal and cardiac alpha-actin gene transcription in muscle. *Mol. Cell. Biol.* 8: 4120-4133.
- [100] Pipes GC, Creemers EE, Olson EN (2006) The myocardin family of transcriptional coactivators: Versatile regulators of cell growth, migration, and myogenesis. *Genes Dev.* 20: 1545-1556.
- [101] Sakuma K, Yamaguchi A (2011) Serum response factor (SRF)-dependent pathway: Potential mediators of growth, regeneration, and hypertrophy of skeletal muscle. In: Pandalai SG, Eds. *Recent Res. Devel. Life Sci.* 5. Research Signpost, Kerala, India, pp. 13-37.
- [102] Soulez M, Rouviere CG, Chafey P, Hentzen D, Vandromme M, Lautredou N, Lamb N, Kahn A, Tuil D (1996) Growth and differentiation of C2 myogenic cells are dependent on serum response factor. *Mol. Cell. Biol.* 16: 6065-6074.
- [103] Sakuma K, Nishikawa J, Nakao R, Nakano H, Sano M, Yasuhara M (2003) Serum response factor plays an important role in the mechanically overloaded plantaris muscle of rats. *Histochem. Cell Biol.* 119: 149-160.
- [104] Gauthier-Rouvière C, Vandromme M, Tuil D, Lautredou N, Morris M, Soulez M, Kahn A, Fernandez A, Lamb N (1996) Expression and activity of serum response factor is required for expression of the muscle-determining factor MyoD in both dividing and differentiating mouse C2C12 myoblasts. *Mol. Biol. Cell* 7: 719-729.
- [105] Charvet C, Houbron C, Parlakian A, Giordani J, Lahoute C, Bertrand A, Sotiropoulos A, Renou L, Schmitt A, Melki J, Li Z, Daegelen D, Tuil D (2006) New role for serum response factor in postnatal skeletal muscle growth and regeneration via the interleukin 4 and insulin-like growth factor 1 pathways. *Mol. Cell. Biol.* 26: 6664-6674.

- [106] Kuwahara K, Barrientos T, Pipes GC, Li S, Olson EN (2005) Muscle-specific signaling mechanism that links actin dynamics to serum response factor. *Mol. Cell. Biol.* 25: 3173-3181.
- [107] Lange S, Xiang F, Yakovenko A, Vihola A, Hackman P, Rostkova E, Kristensen J, Brandmeier B, Franzen G, Hedberg B, Gunnarsson LG, Hughes SM, Marchand S, Sejersen T, Richard I, Edström L, Ehler E, Udd B, Gautel M (2005) The kinase domain of titin controls muscle gene expression and protein turnover. *Science* 308: 1599-1603.
- [108] Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA (2008) A temporal switch from Notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. *Cell Stem Cell* 2: 50-59.
- [109] Brack AS, Rando TA (2008) Age-dependent changes in skeletal muscle regeneration. In: Schiaffino S, Partridge T, Eds. *Skeletal muscle repair and regeneration*. Springer, Dordrecht, pp. 359-374.
- [110] Brack A, Murphy-Seiler F, Hanifi J, Deka J, Eyckerman S, Keller C, Aguet M, Rando TA (2009) BCL9 is an essential component of canonical Wnt signaling that mediates the differentiation of myogenic progenitors during muscle regeneration. *Dev. Biol.* 335: 93-105.
- [111] Le Grand F, Rudnicki MA (2007) Skeletal muscle satellite cells and adult myogenesis. *Curr. Opin. Cell Biol.* 19: 628-633.
- [112] Church V, Francis-West P (2002) Wnt signaling during limb development. *Int. J. Dev. Biol.* 46: 927-936.
- [113] Cossu G, Borello U (1999) Wnt signaling and the activation of myogenesis in mammals. *EMBO J.* 18: 6867-6872.
- [114] Ridgeway A, Petropoulos H, Wilton S, Skerjanc IS (2000) Wnt signaling regulates the function of MyoD and myogenin. *J. Biol. Chem.* 275: 32398-32405.
- [115] Van der Velden J, Langen RC, Kelders MC, Wouters EF, Janssen-Heininger YM, Schols AM (2006) Inhibition of glycogen synthase kinase-3beta activity is sufficient to stimulate myogenic differentiation. *Am. J. Physiol. Cell Physiol.* 290: C453-C462.
- [116] Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, Rando TA (2007) Increased Wnt signaling during aging alters muscle stem cell fate and increased fibrosis. *Science* 317: 807-810.
- [117] Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C (2003) Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. *Am. J. Pathol.* 162: 1495-1502.
- [118] Jiang F, Parsons CJ, Stefanovic B (2006) Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. *J. Hepathol.* 45: 401- 409.
- [119] Jansen KM, Pavlath GK (2008) Molecular control of mammalian myoblast fusion. *Methods Mol. Biol.* 475: 115-133.
- [120] Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. *Curr. Opin. Cell Biol.* 17: 596-603.
- [121] Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. *Cell* 124: 471-484.

- [122] Cuenda A, Cohen P (1999) Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. *J. Biol. Chem.* 274: 4341-4346.
- [123] Erbay E, Chen J (2001) The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. *J. Biol. Chem.* 276: 36079-36082.
- [124] Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. *Nat. Cell Biol.* 3: 1014-1019.
- [125] Park IH, Chen J (2005) Mammalian target of rapamycin (mTOR) signaling is required for a late-stage fusion process during skeletal myotube maturation. *J Biol. Chem.* 280: 32009-32017.
- [126] Sun Y, Ge Y, Drnevich J, Zhao Y, Band M, Chen J (2010) Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. *J. Cell Biol.* 189: 1157-1169.
- [127] Kuang S, Kuroda K, Le Grand F, Rudnicki MA (2007) Asymmetric self-renewal and commitment of satellite stem cells in muscle. *Cell* 129: 999-1010.
- [128] Le Grand F, Jones AE, Seale V, Scimé A, Rudnicki MA (2009) Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. *Cell Stem Cell* 4: 535-547.
- [129] Van Amerongen R, Nusse R (2009) Towards an integrated view of Wnt signaling in development. *Development* 136: 3205-3214.
- [130] Conboy IM, Rando TA (2002) The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. *Dev. Cell* 3: 397-409.
- [131] Cosgrove B, Sacco A, Gilbert PM, Blau HM (2009) A home away from home: Challenges and opportunities in engineering in vitro muscle satellite cell niches. *Differentiation* 78: 185-194.
- [132] Morrison S, Kimble J (2006) Asymmetric and symmetric stem-cell divisions in development and cancer. *Nature* 441: 1068-1074.
- [133] Tajbakhsh S (2009) Skeletal muscle stem cells in developmental versus regenerative myogenesis. *J. Intern. Med.* 266: 372-389.
- [134] Lee SJ (2004) Regulation of muscle mass by myostatin. *Annu. Rev. Cell Dev. Biol.* 20: 61-86.
- [135] Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee SJ (2003) Activation of latent myostatin by the BMP-1/ tolloid family of metalloproteinases. *Proc. Natl. Acad. Sci. USA.* 100: 15842-15846.
- [136] Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ (2002) Induction of cachexia in mice by systemically administered myostatin. *Science* 296: 1486-1488.
- [137] Joulia-Ekaza D, Cabello G (2007) The myostatin gene: physiology and pharmacological relevance. *Curr. Clin. Pharmacol.* 7: 310-315.
- [138] Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R (2002) Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. *J. Biol. Chem.* 277: 49831- 49840.

- [139] Yang W, Zhang Y, Li Y, Wu Z, Zhu D (2007) Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 $\beta$  pathway and is antagonized by insulin-like growth factor 1. *J. Biol. Chem.* 282: 3799-3808.
- [140] McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R (2003) Myostatin negatively regulates satellite cell activation and self-renewal. *J. Cell Biol.* 162: 1135-1147.
- [141] Joulia D, Bernardi H, Garandel V, Rabenoelina F, Vernus B, Cabello G (2003) Mechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatin. *Exp. Cell Res.* 286: 263-275.
- [142] McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma M, Kambadur R (2006) Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. *J. Cell. Physiol.* 209: 501-514.
- [143] McLennan IS (1993) Localisation of transforming growth factor beta 1 in developing muscles: Implications for connective tissue and fiber type pattern formation. *Dev. Dyn.* 197: 281-290.
- [144] Cusella-De Angelis MG, Molinari S, Le Donne A, Coletta M, Vivarelli E, Bouche M, Molinaro M, Ferrari S, Cossu G (1994) Differential response of embryonic and fetal myoblasts to TGF beta: A possible regulatory mechanism of skeletal muscle histogenesis. *Development* 120: 925-933.
- [145] Allen RE, Boxhorn LK (1987) Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. *J. Cell. Physiol.* 133: 567-572.
- [146] Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, Huard J (2004) Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. *Am. J. Pathol.* 164: 1007-1019.
- [147] Serrano AL, Munoz-Canoves P (2010) Regulation and dysregulation of fibrosis in skeletal muscle. *Exp. Cell Res.* 316: 3050-3058.
- [148] Gosselin LE, McCormick KM (2004) Targeting the immune system to improve ventilatory function in muscular dystrophy. *Med. Sci. Sports Exerc.* 36: 44-51.
- [149] Allen RE, Boxhorn LK (1989) Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. *J. Cell. Physiol.* 138: 311-315.
- [150] Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A (2009) Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. *Am. J. Physiol. Cell Physiol.* 297: C1124-C1132.
- [151] Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ (2009) Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. *Am. J. Physiol. Cell Physiol.* 296: C1258-C1270.
- [152] Zádor E, Mendler L, Takács V, De Bleecker J, Wuytack F (2001) Regenerating soleus and extensor digitorum longus muscles of the rat show elevated levels of TNF- $\alpha$  and its receptors, TNFR-60 and TNFR-80. *Muscle Nerve* 21: 1058-1067.
- [153] Warren GL, Hulderman T, Jensen N, McKinstry M, Mishra M, Luster MI, Simoneva PP (2002) Physiological role of tumor necrosis factor  $\alpha$  in a traumatic muscle injury. *FASEB J.* 16: 1630-1632.

- [154] Chen SE, Gerken E, Zhang Y, Zhan M, Mohan RK, Li AS, Reid MB, Li YP (2005) Role of TNF- $\alpha$  signaling in a regeneration of cardiotoxin-injured muscle. *Am J Physiol Cell Physiol* 289: C1179-C1187.
- [155] Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF- $\kappa$ B controls cell growth and differentiation through transcriptional regulation of cyclin D1. *Mol. Cell. Biol.* 19: 5785-5799.
- [156] Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2001) Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor- $\kappa$ B. *FASEB J.* 15: 1169-1180.
- [157] Langen RC, Van der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2004) Tumor necrosis factor- $\alpha$  inhibits myogenic differentiation through MyoD protein destabilization. *FASEB J.* 18: 227-237.
- [158] Langen RC, Schols AM, Kelders MC, Van der Velden JL, Wouters EF, Janssen-Heininger YM (2006) Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. *Am. J. Respir. Cell Mol. Biol.* 35: 689-696.
- [159] Guttridge DC (2004) Signaling pathways weigh in on decisions to make or break skeletal muscle. *Curr. Opin. Clin. Nutr. Metab. Care* 7: 443-450.
- [160] Strle K, Broussard SR, McCusker RH, Shen WH, LeClerc JM, Johnson RW, Freund GG, Dantzer R, Kelley KW (2006) C-jun N-terminal kinase mediates tumor necrosis factor- $\alpha$  suppression of differentiation in myoblasts. *Endocrinology* 147: 4363-4373.
- [161] Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ (1995) Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. *J. Biol. Chem.* 270: 7420-7426.
- [162] Zetser A, Gredinger E, Bengal E (1999) p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. *J. Biol. Chem.* 274: 5193-5200.
- [163] Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F, Feramisco JR, Karim M, Wang JY, Puri PL (2000) p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. *Mol. Cell. Biol.* 20: 3951-3964.
- [164] Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ (1997) Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. *Nature* 386: 296-299.
- [165] Suelves M, Lluís F, Ruiz V, Nebreda AR, Chapman R, Hulderman T, Van Rooijen N, Simeonova PP (2004) Phosphorylation of MRF4 transactivation domain by p38 mediates repression of specific myogenic genes. *EMBO J.* 23: 365-375.
- [166] Pavlath GK, Dominov JA, Kegley KM, Miller JB (2003) Regeneration of transgenic skeletal muscles with altered timing of expression of the basic helix-loop-helix muscle regulatory factor MRF4. *Am. J. Pathol.* 162: 1685-1691.
- [167] Winkles JA (2008) TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and therapeutic targeting. *Nat. Rev. Drug Discov.* 7: 411-425.
- [168] Dogra C, Changotra H, Mohan S, Kumar A (2006) Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor- $\kappa$ B and degradation of MyoD protein. *J. Biol. Chem.* 281: 10327-10336.

- [169] Dogra C, Changothra H, Wedhas N, Qin X, Wergedal JE, Kumar A (2007) TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. *FASEB J.* 21: 1857-1869.
- [170] Dogra C, Hall SL, Wedhas N, Linkhart TA, Kumar A (2007) Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for TWEAK-independent functions of Fn14 during myogenesis. *J. Biol. Chem.* 282: 15000-15010.
- [171] Mittal A, Bhatnagar S, Kumar A, Paul PK, Kuang S, Kumar A (2010) Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. *Am. J. Pathol.* 177: 1732-1742.
- [172] Ying SY, Chang DC, Lin SL (2008) The microRNA (miRNA): Overview of the RNA genes that modulate gene function. *Mol. Biotechnol.* 38: 257-268.
- [173] Bushati N, Cohen SM (2007) microRNA functions. *Annu. Rev. Cell Dev. Biol.* 23: 175-205.
- [174] Ge Y, Chen J (2011) MicroRNAs in skeletal myogenesis. *Cell Cycle* 10: 441-448.
- [175] Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. *Nat. Genet.* 38: 228-233.
- [176] Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF (2006) Myogenic factors that regulate expression of muscle-specific microRNAs. *Proc. Natl. Acad. Sci. USA.* 103: 8721-8726.
- [177] Sokol NS, Ambros V (2005) Mesodermally expressed *Drosophila* microRNA-1 is regulated by Twist and is required in muscles during larval growth. *Genes Dev.* 19: 2343-2354.
- [178] Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X, Wang DZ (2010) microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. *J. Cell Biol.* 190: 867-879.
- [179] Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ (2006) MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. *J. Cell Biol.* 175: 77-85.
- [180] Hirai H, Verma M, Watanabe S, Tastad C, Asakura Y, Asakura A (2010) MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3. *J. Cell Biol.* 191: 347-365.
- [181] Dey BK, Gagan J, Dutta A (2011) miR-206 and -486 induce myoblast differentiation by downregulating Pax7. *Mol. Cell. Biol.* 31: 203-214.
- [182] Cardinali B, Castellani L, Fasanaro P, Basso A, Alema S, Martelli F, Falcone G (2009) MicroRNA-221 and microRNA-222 modulate differentiation and maturation of skeletal muscle cells. *PLoS One* 4: e7607.